Effects of rosiglitazone on the expression of PPAR-γ and the production of IL-6 and IL-8 in acute lung injury model using human pulmonary epithelial cells

Tropical Journal of Pharmaceutical Research

Volumn 10, Issue 5, 2011, Pages 559-566

  Kim, Sung Kyoung ^a   Park, Chan Kwon ^a   Lee, Sook Young ^a   Song, Jeong Sup ^a   Park, Sung Hak ^a   Kim, Young Kyoon ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Acute lung injury; IL 6; IL 8; PPAR ; Rosiglitazone

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ARTICLE; CELL DENSITY; CELL LYSATE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 80655131111     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Schutte H, Lohmeyer J, Rosseau S, Ziegler S, Siebert C, Kielisch H, Pralle H, Grimminger F, Morr H, Seeger W. Bronchoalveolar and systemic cytokine profiles in patients with ARDS, severe pneumonia and cardiogenic pulmonary oedema. Eur Respir J 1996; 9: 1858-1867.
2. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-1349.
3. Suratt BT, Parsons PE. Mechanisms of acute lung injury/acute respiratory distress syndrome. Clin Chest Med 2006; 27: 579-589; abstract viii.
4. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-895.
5. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activatedreceptors(PPARs): tissue distribution of PPAR-alpha, -beta, and - gamma in the adult rat. Endocrinology 1996; 137: 354-366.
6. Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 2000; 448: 121-138.
7. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-389.
8. Pawliczak R, Han C, Huang XL, Demetris AJ, Shelhamer JH, Wu T.85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells. J Biol Chem 2002; 277: 33153-33163.
9. Wang AC, Dai X, Luu B, Conrad DJ. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 2001; 24: 688-693.
10. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 1994; 91: 7355-7359.
11. Green S. PPAR: a mediator of peroxisome proliferator action. Mutat Res 1995; 333: 101-109.
12. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354: 141-148.
13. Bailey ST, Ghosh S. 'PPAR'ting ways with inflammation. Nat Immunol 2005; 6: 966-967.
14. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. Theperoxisomeproliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
15. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Eur J Pharmacol 2004; 483: 79-93.
16. Abdelrahman M, Sivarajah A, Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 2005; 65: 772-781.
17. Liaudet L, Mabley JG, Pacher P, Virag L, Soriano FG, Marton A, Hasko G, Deitch EA, Szabo C. Inosineexertsa broad range of antiinflammatory effects in a murine model of acute lung injury. Ann Surg 2002; 235: 568-578.
18. Martin MA, Silverman HJ. Gram-negative sepsis and the adult respiratory distress syndrome. Lin Infect Dis 1992; 14: 1213-1228.
19. Welbourn CR, Young Y. Endotoxin, septic shock and acute lung injury: neutrophils, macrophages and inflammatory mediators. Br J Surg 1992; 79: 998-1003.
20. Liu D, Zeng BX, Zhang SH, Wang YL, Zeng L, Geng ZL, Zhang SF. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats. Crit Care Med 2005; 33: 2309-2316.
21. Ito K, Shimada J, Kato D, Toda S, Takagi T, Naito Y, Yoshikawa T, Kitamura N. Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats. Eur J Cardiothorac Surg 2004; 25: 530-536.
22. Inoue K, Takano H, Yanagisawa R, Ichinose T, Sadakane K, Yoshino S, Yamaki K, Uchiyama K, Yoshikawa T. Effects of15-deoxy- Delta12,14-prostaglandin J2 on the expression of Toll-like receptor 4 and 2 in the murine lung in the presence of lipopolysaccharide. Clin Exp Pharmacol Physiol 2005; 32: 230-232.
23. Hinz B, Brune K, Pahl A. 15-Deoxy-Delta(12,14)- prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-gamma-independent mechanism. Biochem Biophys Res Commun 2003; 302: 415-420.
24. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48-52.
25. Seargent JM, Yates EA, Gill JH. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 2004; 143: 933-937.
26. Derlacz RA, Hyc K, Usarek M, Jagielski AK, Drozak J, Jarzyna R. PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney- cortex tubules. Biochem Cell Biol 2008; 86: 396-404.
27. Turturro F, Friday E, Fowler R, Surie D, Welbourne T. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator- activated receptor gamma-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 2004; 10: 7022-7030.
28. Perez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S, Jordan J, Cena V, Llopis J. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 2004; 279: 8976-8985.
29. Scatena R, Bottoni P, Martorana GE, Ferrari F, De Sole P, Rossi C, Giardina B. Mitochondrial respiratory chain dysfunction, a non-receptor- mediated effect of synthetic PPAR-ligands: biochemical and pharmacological implications. Biochem Biophys Res Commun 2004; 319: 967-973.
30. Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET, Mathews WR. Identification of a novel mitochondrial protein (mitoNEET) cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 2004; 286: E252-260.